沙美特罗替卡松粉吸入剂治疗尘肺并发慢性阻塞性肺疾病急性加重期的疗效观察

目的：观察沙美特罗替卡松粉吸入剂对尘肺并发慢性阻塞性肺疾病急性加重期（AECOPD）的疗效。方法：选取73例尘肺并发AECOPD患者,以随机抽样法分为对照组（35例）和观察组（38例）,2组患者均接受吸氧、抗炎、止咳等常规治疗,在此基础上,对照组使用氨茶碱,观察组使用沙美特罗替卡松粉吸入剂解痉止喘。3个月后,观察患者临床症状改善情况,检测患者肺功能、动脉血气分析。结果：治疗后观察组患者总有效率（35/38,92.1%）显著高于对照组（25/35,71.4%）,P〈0.01;治疗后观察组患者肺功能及血气分析指标均明显优于对照组（P〈0.05、P〈0.01）,且未见不良反应发生。结论：沙美特罗替卡松粉吸入剂是治疗尘肺并发AECOPD安全、有效的药物,可改善患者的生存质量。

Clinical Efficacy of Salmeterol Xinafoate and Patients with Pneumonoconiosis Complicated Fluticasone Propionate Powder for Inhalation for with Acute Exacerbations of Chronic Obstructive Pulmonary Disease

OBJECTIVE ：To observe the chnica efficacy of salmeterol xinafoate and fluticasone propionate powder for inhalation for patients with pneumonoconiosis complicated with acute exacerbation of chronic obstructive pulmonary disease （AECOPD）. METHODS： 73 patients with pneumoconiosis complicating with AECOPD were randomized to either control group （ n --- 35 ） or observation group （ n = 38 ）. Both groups were assigned to receive oxygen, anti- inflammatory and anti-cough therapy. However, the control group received add-on aminophylline while the observation group received add-on salmeterol xinafoate and fluticasone propionate powder for inhalation （an antispasmodic and antiasthmatic agent）. Three months later, patients＇ improvement in clinical symptoms were observed, and patients＇ pulmonary function were tested and arterial blood gas analysis was performed. RESULTS： After treatment, the total effective rate in the observation group was significantly higher than in the group （35/38, 92. 1% ） vs. （25/35, 71.4% ） （P 〈 0. 01 ）~. After treatment, the observation group was significantly superior to the control group in pulmonary function and blood gas analysis parameters （ P 〈 0.05, P 〈 0.01 ）, and no adverse reactions were noted. CONCLUSION： Salmeterol xinafoate and fluticasone propionate powder for inhalation was proved to be a safe and effective therapy for patients with pneumonoconiosis complicated with acute exacerbation of chronic obstructive pulmonary disease （AECOPD） and it resulted in improvement of patient＇s quality of life.